Protein Kinase C Isozymes, Novel Phorbol Ester Receptors and Cancer Chemotherapy

Author(s): Orla P. Barry, Marcelo G. Kazanietz.

Journal Name: Current Pharmaceutical Design

Volume 7 , Issue 17 , 2001

Become EABM
Become Reviewer

Abstract:

Recent years have seen extensive growth in the understanding of the role(s) of the various PKC isozymes and novel receptors for the phorbol ester tumor promoters. The PKC family of serine-threonine kinases is an important regulator of signaling cascades that control cell proliferation and death, and therefore represent targets for cancer therapy. While past interests have focused on PKC-selective inhibitors, more recently, intensive research has been underway for selective activators and inhibitors for each individual PKC isozyme. In the past few years a large number of PKC activators and inhibitors with potential as anticancer agents have been developed. A number of these compounds are already in Phase II clinical testing. As a new generation of cancer chemotherapeutic agents are designed, developed and put through a series of rigorous clinical trials, we can anticipate achieving exquisite control over PKCmediated regulatory pathways, leading ultimately to a greater understanding of different cancers.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 7
ISSUE: 17
Year: 2001
Page: [1725 - 1744]
Pages: 20
DOI: 10.2174/1381612013397041
Price: $65

Article Metrics

PDF: 3